Abstract 618P
Background
Renal Ewing’s sarcoma/primitive neuroectodermal tumor (ES/PNET) among adults is an extremely rare malignancy. Accurate diagnosis mandates detailed immunohistochemistry (IHC) and molecular characterization. There is limited data on the treatment of these patients. We present a clinicopathological and molecular profile of renal ES/PNET from a single South Indian tertiary referral center.
Methods
We conducted a retrospective study of adults with a histopathological diagnosis of renal ES/PNET treated at our center over the last 20 years. All patients had received a standard treatment protocol of VAC/IE. Principal outcomes were event-free survival (EFS), overall survival (OS) and adverse events during treatment.
Results
We included 25 patients with renal ES treated at our center from 2003-2023. 68% were male, with median age 29(18-53). 8(32%) had localised disease and 17(68%) had recurrent/metastatic disease; lung(36%) and bone(28%) were the common sites of metastases. Median tumour size was 13.5cm and renal vein/IVC thrombus was present in 11(55%) patients. IHC(done in 24 patients), showed CD99 +, NKX 2.2 + in 100% and FLI1 + in 93.7%. RT-PCR/FISH done in 15 patients revealed EWS-FLI1 translocations in 5 patients, 4 of which were Type 1. Nephrectomy was performed in 19 patients: 8 radical for non-metastatic and 11 palliative for metastatic disease. 16 received systemic therapy, the median number of cycles being 10(Range:2-16). 11 patients received concurrent radiation. Grade 3/4 anaemia, thrombocytopenia, neutropenia, and febrile neutropenia was seen in 1(6.6%),1(6.6%),8(50%) and 8(50%) patients respectively during VAC/IE. Only 50% of patients had long term follow up. Survival at 3 years is 64.3%(83% for localised disease, 57.3% for recurrent/metastatic).
Conclusions
This study represents a substantial cohort of adult patients with renal ES/PNET undergoing a unified treatment approach. Predominantly, tumors presented as extensive and locally aggressive with favourable survival for localised disease. While these observations offer valuable insights, the rarity of the disease underscores the need for larger, multicentric studies for more definitive conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract